个人简介
Professor Martin is a dual trained clinical pharmacologist and practising general physician. She has studied politics and health economics at Oxford University as a Rhodes Scholar and has used this experience to serve on the Pharmaceutical Benefits Advisory Committee, the Economic Subcommittee of the PBAC and other Government and Statewide committees examining appropriate allocation, regulation, safety and efficacy in pharmaceuticals. She is a Member of the Australian Institute of Company Directors (Diploma).
Her PhD (Monash) examined innate immunity in Type 2 diabetes and subsequent postdoctoral work at the Walter and Eliza Hall focussed on the function of macrophages with high fat diet. Her recent research is in the area of clinical development of both novel and old drugs for a variety of diseases and has developed a collaboration with Leiden University using clinical pharmacological methods generally to improve dosing, with EKUT (Germany) in the combined role of therapeutic drug monitoring (TDM) and pharmacogenetics to individualise choice and dose of chemotherapy, and with the National Institutes of Health in identifying and managing synthetic drugs of abuse.
Her current PhD students are researching cannabinoid therapies, targeted cancer therapies, dosing in neonates and therapeutic drug monitoring in clinical care including with antimicrobial therapies. Professor Martin is passionate about teaching in the area of clinical pharmacology and been involved in curriculum development for medical students (Otago, Monash, Queensland and Melbourne Universities) was the recent teaching and learning representative on the STC in clinical pharmacology for the College of Physicians (RACP). She is currently a member of the RACP Policy and Advocacy Committee, the Council of the Australasian Society for Clinical and Experimental Pharmacology and Therapeutics, and a member of the Pharmacology and Therapeutics Advisory Committee of PHARMAC, the sole purchaser for pharmaceuticals in New Zealand.
近期论文
查看导师新发文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
2016 Ward MB, Reuter SE, Martin JH, 'How 'Optimal' are Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations.', Clin Pharmacokinet, (2016)
2016 Bonomo Y, Zundel S, Martin JH, 'Addressing unconscious bias for female clinical academics.', Intern Med J, 46 391-393 (2016)
2016 Reuter SE, Martin JH, 'Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome.', Clin Pharmacokinet, 55 807-812 (2016)
2016 Skinner TR, Scott IA, Martin JH, 'Diagnostic errors in older patients: A systematic review of incidence and potential causes in seven prevalent diseases', International Journal of General Medicine, 9 137-146 (2016) [C1]
2016 Meiklejohn JA, Mimery A, Martin JH, Bailie R, Garvey G, Walpole ET, et al., 'The role of the GP in follow-up cancer care: a systematic literature review', Journal of Cancer Survivorship, 1-22 (2016)
2016 Meiklejohn JA, Adams J, Valery PC, Walpole ET, Martin JH, Williams HM, Garvey G, 'Health professional's perspectives of the barriers and enablers to cancer care for Indigenous Australians', European Journal of Cancer Care, 25 254-261 (2016) [C1]
2016 Lucas C, Byles J, Martin JH, 'Medicines optimisation in older people: Taking age and sex into account.', Maturitas, (2016)
2016 Martin J, Shenfield G, 'The hazards of rapid approval of new drugs', Australian Prescriber, 39 2-3 (2016)
2016 Denaro C, Martin J, 'The challenge of costly drugs', Australian Prescriber, 39 72-74 (2016)
2016 Moore SP, Soerjomataram I, Green AC, Garvey G, Martin J, Valery PC, 'Breast cancer diagnosis, patterns of care and burden of disease in Queensland, Australia (1998¿2004): does being Indigenous make a difference?', International Journal of Public Health, 61 435-442 (2016)
2016 McDougall DAJ, Martin J, Playford EG, Green B, 'The Impact of Model-Misspecification on Model Based Personalised Dosing', AAPS Journal, 1-10 (2016)
2016 Garvey G, Cunningham J, He VY, Janda M, Baade P, Sabesan S, et al., 'Health-related quality of life among Indigenous Australians diagnosed with cancer', QUALITY OF LIFE RESEARCH, 25 1999-2008 (2016)
2016 Petrie S, Barras M, Lust K, Fagermo N, Allen J, Martin JH, 'Evaluation of therapeutic enoxaparin in a pregnant population at a tertiary hospital', Internal Medicine Journal, 46 826-833 (2016) [C1]
2016 Rundle-Thiele D, Head R, Cosgrove L, Martin JH, 'Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma', British Journal of Clinical Pharmacology, 81 199-209 (2016) [C1]
2016 Hayward KL, Powell EE, Irvine KM, Martin JH, 'Can paracetamol (acetaminophen) be administered to patients with liver impairment?', British Journal of Clinical Pharmacology, 81 210-222 (2016) [C1]
2016 Goulooze SC, Galettis P, Boddy AV, Martin JH, 'Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours', CANCER CHEMOTHERAPY AND PHARMACOLOGY, 78 209-216 (2016) 2016 Martin JH, Bonomo YA, 'Medicinal cannabis in Australia: the missing links.', Med J Aust, 204 371-373 (2016)
2016 Fay MF, Head R, Sminia P, Dowson N, Cosgrove L, Rose SE, Martin JH, 'Valproate in Adjuvant Glioblastoma Treatment.', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, (2016)
2015 O'Hara K, Wright IMR, Schneider JJ, Jones AL, Martin JH, 'Pharmacokinetics in neonatal prescribing: Evidence base, paradigms and the future', British Journal of Clinical Pharmacology, 80 1281-1288 (2015) [C1]
2015 Martin JH, Ferro A, 'From an evolutionary perspective, all 'new' antimicrobial targets are old: Time to think outside the box', British Journal of Clinical Pharmacology, 79 165-167 (2015) [C3]
京公网安备 11010802027423号